Trial Profile

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CGC 729 (Primary) ; Cyclophosphamide; Fludarabine
Indications Solid tumours
Focus First in man; Therapeutic Use

Most Recent Events

23 May 2024 According to a Cure Genetics media release, as of April 2024, five patients were enrolled and received a single infusion of CGC729.
23 May 2024 According to a Cure Genetics media release, results from this trial were presented at the at the 27th Annual Meeting of the American Society for Gene & Cell Therapy (ASGCT) in Baltimore.
23 May 2024 Results presented in the Cure Genetics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com